A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests

Executive Chairman Matthew Rabinowitz reported a sale of 2,000 shares of Natera, Inc. (NASDAQ:NTRA) in a recent SEC Form 4 filing.

Transaction summary

Metric	Value
Transaction value	$641,800
Shares sold (indirectly held)	2,000
Post-transaction shares	2,277,394
Post-transaction shares (directly held)	2,275,394
Post-transaction shares (indirectly held)	2,000
Post-transaction value	$733.6 million

Transaction value based on SEC Form 4 weighted average sale price ($320.90); post-transaction value based on the August 7 market close ($322.10).

Key questions

• What was the regulatory context of the transaction?
  The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Rabinowitz on December 5, 2025, which allows for scheduled transactions to manage liquidity while avoiding concerns regarding material non-public information.
• How does this transaction impact the insider's overall stake?
  The sale of 2,000 shares was limited to the indirect holdings held by a spouse, leaving the insider's direct position of 2,275,394 shares unchanged in this transaction.
• What has been the recent performance trend for Natera?
  As of the transaction date, the stock had achieved a one-year return of 128%, while the company reported trailing-12-month revenue of $2.7 billion and a net loss of $192.3 million.

Company Overview

Metric	Value
Share Price (as of market close 2026-08-06)	$265.38
Market Capitalization	$46.1 billion
Revenue (TTM)	$2.7 billion
Net Income (TTM)	-$192.3 million

Company Snapshot

• Natera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama for non-invasive prenatal testing (NIPT), Vistara for single-gene disorder screening, and Horizon for carrier screening, generating revenue through direct laboratory testing services and licensing arrangements.
• The company operates a laboratory-based diagnostic services business model, generating revenue by performing molecular tests on patient samples submitted by healthcare providers and consumers, with results delivered to clinicians for clinical decision-making.
• Natera serves obstetrics and gynecology practices, reproductive endocrinology clinics, genetic counselors, and healthcare systems globally, with primary customers including pregnant women and individuals seeking genetic risk assessment and carrier screening.

Natera is a leading molecular diagnostics company with a market capitalization of $46.1 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the genetic testing and prenatal diagnostics market. The company has demonstrated substantial growth momentum, with a staggering one-year stock price gain of 128%, reflecting strong market confidence in its diagnostic platforms and expansion strategy. Natera's competitive advantage derives from its proprietary molecular testing technology, comprehensive test portfolio addressing multiple clinical indications, and established relationships with healthcare providers across obstetrics, oncology, and reproductive health markets.

What this transaction means for investors

Not a single one of Rabinowitz's own direct shares moved here. The 2,000 shares sold came entirely from a spouse's account, leaving his personal stake of more than 2.27 million shares exactly where it was, so even the word "sold" oversells what the co-founder did in this filing. It ran on a scheduled plan, and it is the kind of household portfolio adjustment that carries no read on the company whatsoever.

Meanwhile, Natera just had a banner quarter, growing second-quarter revenue about 38% to $753 million, which cleared expectations, and lifted its full-year guidance thanks to its Signatera cancer-detection test and record testing volumes. The stock has roughly doubled over the past year and recently pushed toward all-time highs. CFO Mike Brophy told investors that guidance "assumes stable Signatera pricing" for the balance of the year, leaving room for more if prices rise. Meanwhile, Rabinowitz’s stake looks largely intact; he had a sale before earnings, but it was even smaller and tied to vesting, so it seemed similarly negligible. More importantly, he’s amassed a billionaire fortune including stock options tied to the company, so he’s clearly aligned with shareholders.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.